Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VALSARTAN
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
- A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- Initiation of ARNi and SGLT2i in Patients With HFrEF
- Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
- Sacubitril/Valsartan Versus Valsartan in Heart Failure
- Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
- Angiotensin Receptor-Neprilysin Inhibitor After Transcatheter Aortic Valve Implantation
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
- Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
- Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
- The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
- Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
- Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
- Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- Enhancing the Natriuretic Peptide System in HFpEF
- Sacubitril/Valsartan for CKD5 Stage Dialysis Patients With Heart Failure
- Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
- Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
- 24 Hour Ambulatory Cardiac Oxygen Consumption
- Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
- Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
- Effect of HMP on Diabetic Microangiopaemia in T2DM
- The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
- Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome
- Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
- Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
- The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
- Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
- A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
- Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine
- Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
- The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Sacubitril/Valsartan in Resistant Hypertension
- Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules
- Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
- The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
- Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
- Telmisartan for Treatment of COVID-19 Patients
- Early Treatment of ARNI on Myocardial Remodeling and Progress
- Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
- Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis
- NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
- Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output
- Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
- Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
- Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
- Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
- Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI
- Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
- Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
- Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
- A Bioequivalence Study of Valsartan / Amlodipine From Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland)
- NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
- A Study of LY900020 in Healthy Chinese Participants
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level
- Changes in NT-proBNP and Outcomes, Safety, and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
- LCZ696 in Advanced LV Hypertrophy and HFpEF
- COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
- An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
- Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
- The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction
- Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
- Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
- Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation
- CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure
- Prevention of Cardiac Dysfunction During Breast Cancer Therapy
- PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
- Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
- Nighttime Valsartan in Hemodialysis Hypertension
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH
- Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
- The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
- A Polypill for Secondary Prevention of Ischemic Heart Disease
- Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
- Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
- Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
- Prevention of Cardiovascular Disease With Polypill Among Pars Cohort Participants
- Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women
- Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure
- Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
- Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
- Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan
- The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
- Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
- Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
- The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure
- Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
- Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
- Comparing ARNI With ACE Inhibitor on Endothelial Function
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
- Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension
- Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
- PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
- randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
- Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
- Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
- Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
- The DDI Study of SP2086 and Valsartan
- EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- The Drug-drug Interaction of SP2086 and Valsartan
- Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
- Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
- Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
- Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
- Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
- Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
- Chronopharmacology of Valsartan in Normotensive Subjects
- Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients
- Physiologic Interactions Between the Adrenal- and the Parathyroid Glands
- Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
- A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)
- Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg
- Fimasartan Achieving SBP Target (FAST) Study
- Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
- Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients
- Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan
- Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
- Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
- Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
- Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions
- Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions
- MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
- Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan
- Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects
- Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
- Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects
- Intermittent Hypoxia 2: Cardiovascular and Metabolism
- PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
- Prevention of Anthracycline-induced Cardiotoxicity
- Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers
- Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg
- Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
- Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
- Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
- Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)
- A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
- A Drug Interaction Study of Cilnidipine and Valsartan
- Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers
- Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
- Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome
- Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients
- Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)
- Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide
- Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
- Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
- A Trial of Fimasartan for Early Diastolic Heart Failure
- Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
- A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
- Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
- New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering
- Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
- Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
- Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension
- Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
- Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
- Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients
- The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome
- Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
- Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
- Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
- Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
- Blood Pressure Lowering in Acute Stroke Trial
- Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
- ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria
- Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
- Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
- The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling
- Effects of Saxagliptin on Endothelial Function
- Aliskiren on Retinal Vasculature Treatment Study
- An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
- Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.
- A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
- Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)
- Recurrent Stroke Prevention Clinical Outcome Study
- Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
- Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
- Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
- A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers
- Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics
- Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
- FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
- To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
- Additive Effects of Pravastatin and Valsartan
- Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
- Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
- Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus
- Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension
- Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
- Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
- Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
- Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
- A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
- Valsartan Intensified Primary Care Reduction of Blood Pressure Study
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
- Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
- Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke
- The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
- Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
- Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
- 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
- Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)
- Regression of Fatty Heart by Valsartan Therapy
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
- Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
- Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
- Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis
- Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients
- Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients
- Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
- Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
- Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
- Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage
- The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
- Black Education and Treatment of Hypertension (BEAT HTN)
- Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril
- Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
- Blood Pressure Lowering in Acute Stroke Trial (BLAST)
- Combined Renin Inhibition/Beta-blockade
- Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes
- Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
- Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent
- Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients
- To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
- Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
- Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension
- BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
- Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
- The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
- To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)
- To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
- Preventing Microalbuminuria in Type 2 Diabetes
- Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
- Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
- Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
- Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study
- A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
- Prevention of Diabetes and Hypertension
- Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
- Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
- Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
- Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
- Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
- Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
- Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
- A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
- Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
- Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
- Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
- To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers
- Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
- Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
- One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension
- Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.
- Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
- Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
- Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients
- Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension
- Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
- Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
- A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients
- Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
- Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
- GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence
- Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine
- Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
- Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
- Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
- Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
- The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
- Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
- Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension
- 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
- A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy
- Angiotensin II Antagonism of TGF-Beta 1
- A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
- Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker
- Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS
- Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
- Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose
- A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
- Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?
- Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
- Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
- Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
- A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
- A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
- Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
- A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
- Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
- The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
- Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
- Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
- A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
- A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
- SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
- A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
- Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
- Effect of Valsartan on Carotid Artery Disease
- Rationale and Design for Shiga Microalbuminuria Reduction Trial
- Statins in Proteinuric Nephropathies
- Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
- The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
- Hypertension and Cardiovascular Risk Factors
- Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
- Antialbuminuric Effects of Valsartan and Lisinopril
- Antiproteinuric Effect of Valsartan and Lisinopril
- Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
- Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
- A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
- Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
- VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
- A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
- Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure
- A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
- VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
- Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
- A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
- A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
- Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
- Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
- A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
- Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
- To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
- Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
- Prevention of CHOP-induced Chronic Cardiotoxicity
- 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)
- Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
- A Morbidity-Mortality and Remodeling Study With Valsartan
- Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
- Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
- Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
- Optimal Treatment for Kidney Disease in HIV Infected Adults
- Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Clinical trials list
click for details